This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

PKU
+1

GMP Case Studies of Tolerance, Safety and Acceptability in PKU and TYR

Sponsored by Nutricia UK Ltd

About this trial

Last updated 2 years ago

Study ID

GMP2020

Status

Completed

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
3+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 2 years ago

What is this trial about?

Three new protein substitutes have been developed to help with compliance in PKU and TYR patients, which are powdered protein substitutes, low in Phe and, low in Phe and Tyr respectively, with a mixed balance of glycomacropeptide (GMP), essential and non-essential amino acids, carbohydrates, fats and micronutrients for the dietary management of PKU and TYR. This series of case-studies will evaluate the acceptability, compliance, gastrointestinal tolerance and safety of the three GMP-based products for PKU and TYR in 45 patients with PKU and TYR, in both adults and children over 3 years (15 patients per product). The case study will last 29 days in total, including a 1-day baseline period followed by a 28-day intervention period. The case studies will be conducted across multiple specialist metabolic centres in the UK, to meet the UK ACBS and GMS requirements for acceptability studies. A series of case studies is undertaken due to the rarity of these conditions and the difficulty in recruiting these patients to trials.

What are the participation requirements?

Yes

Inclusion Criteria

- Male or female

- Over 3 years of age

- Diagnosed with classical or variant type phenylketonuria, or tyrosinaemia (as appropriate)

- Have been compliant in taking at least one protein substitute, providing at least 10g protein equivalents, for at least 1 month prior to trial commencement

- Have a prescribed daily Phe or Phe and Tyr allowance for PKU or TYR respectively

- Written or electronic informed consent from patient, and/or from parent/caregiver if applicable

No

Exclusion Criteria

- Currently prescribed Sapropterin or similar tetrahydrobiopterin based medication

- Pregnant or lactating

- Requiring parenteral nutrition

- Major hepatic or renal dysfunction

- Participation in other studies within 1 month prior to entry of this study

- Allergy to any of the study product ingredients, including milk and soy

- Investigator concern around willingness/ability of patient or parent/caregiver to comply with protocol requirements

Locations

Location

Status